Incorporating Patient Perspectives into Structured Benefit-Risk Assessment: A Drug Development Framework Recommendation
Therapeutic Innovation & Regulatory Science · 2026-05 · 60 (3) · 713-724
DOI: 10.1007/s43441-026-00940-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 08.03.2026. Verfasst von Emuella Flood und 7 weiteren Autor:innen. Beteiligte Einrichtung: Patient Centered Science, BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, USA. Hauptthemen laut MEDLINE: Drug Development. Die Arbeit nennt 40 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Regulatory agencies have been promoting the incorporation of the patient perspective into benefit-risk assessment to better align regulatory decisions with patients' needs and priorities. Currently, benefit-risk assessments for regulatory submissions primarily capture the patient perspective through patient-reported outcome data from clinical trials. However, there is a push for a more systematic approach to capturing the patient perspective in benefit-risk assessment and decision-making throughout the drug development life cycle. Although different guidelines and frameworks have been developed, consensus on how to systematically incorporate the patient perspective into structured benefit-risk (sBR) assessment remains elusive. In 2023, Sullivan et al. published an sBR assessment framework that was developed to enhance systematic and collaborative decision-making throughout a drug life cycle. Here we propose how this sBR assessment framework could be expanded, committing to a patient-centered approach by considering the patient perspective at every step of drug development. These recommendations aim to put patients at the center of drug development, ultimately leading to better treatment outcomes and improved lives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Patient Centered Science, BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, USA.
- Patient Centered Science, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
- Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden.
- Global Patient Safety Oncology, AstraZeneca, Cambridge, UK.
- Global Patient Safety BioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA.
- R&D Patient Science, AstraZeneca, Gothenburg, Sweden.
Förderung
- AstraZeneca
Zitieren
APA
Flood, E., Karlsson, N., Ostridge, J., Kirova, B., Sullivan, T., Zörényi, G., Valastro, B., & Park, J. (2026). Incorporating Patient Perspectives into Structured Benefit-Risk Assessment: A Drug Development Framework Recommendation. Therapeutic Innovation & Regulatory Science, 60(3), 713-724. https://doi.org/10.1007/s43441-026-00940-0
Vancouver
Flood E, Karlsson N, Ostridge J, Kirova B, Sullivan T, Zörényi G, et al. Incorporating Patient Perspectives into Structured Benefit-Risk Assessment: A Drug Development Framework Recommendation. Therapeutic Innovation & Regulatory Science. 2026;60(3):713-724. doi:10.1007/s43441-026-00940-0
BibTeX
@article{Flood2026,
author = {Flood, Emuella and Karlsson, Niklas and Ostridge, Jennifer and Kirova, Bistra and Sullivan, Tim and Zörényi, György and Valastro, Barbara and Park, Jiyoon},
title = {Incorporating Patient Perspectives into Structured Benefit-Risk Assessment: A Drug Development Framework Recommendation},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
volume = {60},
number = {3},
pages = {713--724},
doi = {10.1007/s43441-026-00940-0}
}
EUVIMED